Secondary cytoreductive surgery potentially improves the oncological outcomes of patients with recurrent uterine sarcomas

Nakamura,Kenichi; Kajiyama,Hiroaki; Utsumi,Fumi; Suzuki,Shiro; Niimi,Kaoru; Sekiya,Ryuichiro; Sakata,Jun; Yamamoto,Eiko; Shibata,Kiyosumi; Kikkawa,Fumitaka

doi:10.3892/mco.2018.1560

Secondary cytoreductive surgery potentially improves the oncological outcomes of patients with recurrent uterine sarcomas

Authors:
- Kenichi Nakamura
- Hiroaki Kajiyama
- Fumi Utsumi
- Shiro Suzuki
- Kaoru Niimi
- Ryuichiro Sekiya
- Jun Sakata
- Eiko Yamamoto
- Kiyosumi Shibata
- Fumitaka Kikkawa
View Affiliations

Affiliations: Department of Obstetrics and Gynecology, Graduate School of Medicine, Nagoya University, Nagoya 466‑8550, Japan, Department of Healthcare Administration, Graduate School of Medicine, Nagoya University, Nagoya 466‑8550, Japan, Department of Obstetrics and Gynecology, Banbuntane Hotokukai Hospital, Fujita Health University, Nagoya 454-8509, Japan
Published online on: January 19, 2018 https://doi.org/10.3892/mco.2018.1560
Pages: 499-503

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Uterine sarcomas are some of the most malignant and aggressive tumor types among the gynecologic malignancies, and they are associated with a high rate of recurrence and a poor prognosis. Due to their rarity and diversity, the optimal treatment for recurrent uterine sarcomas has not yet been elucidated. The aim of the present study was to investigate the potential of secondary cytoreductive surgery (SCS) for patients with recurrent uterine sarcomas. A total of 18 patients with recurrent uterine sarcomas were retrospectively identified at the Department of Obstetrics and Gynecology, Nagoya University (Nagoya, Japan) between January 2002 and December 2015. This included 8 patients with leiomyosarcoma, 6 with carcinosarcoma, 3 with endometrial stromal sarcoma and 1 with adenosarcoma. All patients underwent primary debulking surgery as the initial treatment. In summary, 9 patients were treated with SCS when they experienced their first recurrence, and the other 9 patients were treated with non‑SCS methods, including chemotherapy or radiotherapy. In the SCS group, 5/9 patients had confined pelvic recurrences, 3 patients had extra‑pelvic diseases, including pulmonary metastasis, and one patient had intra‑ and extra‑pelvic recurrence. The 3‑year overall survival (OS) rates were 77.8 and 11.1% in the SCS and non‑SCS groups, respectively. The patients who underwent SCS experienced a significantly longer OS time compared with those in the non‑SCS group (P=0.006). In addition, the disease‑free survival after second‑line therapy was significantly longer in the SCS group than in the non‑SCS group (P=0.0496). These findings suggest that resection of recurrent uterine sarcomas may be beneficial for the improvement of patient survival. Prospective studies with sufficient statistical power are warranted for further evaluation of the effect of SCS.

View Figures

View References

1	Park JY, Kim DY, Suh DS, Kim JH, Kim YM, Kim YT and Nam JH: Prognostic factors and treatment outcomes of patients with uterine sarcoma: Analysis of 127 patients at a single institution, 1989–2007. J Cancer Res Clin Oncol. 134:1277–1287. 2008. View Article : Google Scholar : PubMed/NCBI
2	Burghaus S, Halmen S, Gass P, Mehlhorn G, Schrauder MG, Lux MP, Renner SP, Beckmann MW, Hein A and Thiel FC: Outcome and prognosis in uterine sarcoma and malignant mixed Mullerian tumor. Arch Gynecol Obstet. 294:343–351. 2016. View Article : Google Scholar : PubMed/NCBI
3	Fujita H, Adachi S, Kigawa J, Sugiyama T and Takeuchi S: A clinicopathlogical study of uterine sarcoma in last decade-a retrospective study of KCOG/USSG inter group study. Adv Obstet Gynecol. 56:463–465. 2004.
4	Giuntoli RL II, Garrett-Mayer E, Bristow RE and Gostout BS: Secondary cytoreduction in the management of recurrent uterine leiomyosarcoma. Gynecol Oncol. 106:82–88. 2007. View Article : Google Scholar : PubMed/NCBI
5	Mayerhofer K, Obermair A, Windbichler G, Petru E, Kaider A, Hefler L, Czerwenka K, Leodolter S and Kainz C: Leiomyosarcoma of the uterus: A clinicopathologic multicenter study of 71 cases. Gynecol Oncol. 74:196–201. 1999. View Article : Google Scholar : PubMed/NCBI
6	Leath CA III, Huh WK, Hyde J Jr, Cohn DE, Resnick KE, Taylor NP, Powell MA, Mutch DG, Bradley WH and Geller MA: A multi-institutional review of outcomes of endometrial stromal sarcoma. Gynecol Oncol. 105:630–634. 2007. View Article : Google Scholar : PubMed/NCBI
7	Callister M, Ramondetta LM, Jhingran A, Burke TW and Eifel PJ: Malignant mixed mullerian tumors of the uterus: Analysis of patterns of failure, prognostic factors and treatment outcome. Int J Radiat Oncol Biol Phys. 58:786–796. 2004. View Article : Google Scholar : PubMed/NCBI
8	Anraku M, Yokoi K, Nakagawa K, Fujisawa T, Nakajima J, Akiyama H, Nishimura Y and Kobayashi K; Metastatic Lung Tumor Study Group of Japan, : Pulmonary metastases from uterine malignancies: Results of surgical resection in 133 patients. J Thorac Cardiovasc Surg. 127:1107–1112. 2004. View Article : Google Scholar : PubMed/NCBI
9	Anderson TM, McMahon JJ, Nwogu CE, Pombo MW, Urschel JD, Driscoll DL and Lele SB: Pulmonary resection in metastatic uterine and cervical malignancies. Gynecol Oncol. 83:472–476. 2001. View Article : Google Scholar : PubMed/NCBI
10	Levenback C, Rubin SC, McCormack PM, Hoskins WJ, Atkinson EN and Lewis JL Jr: Resection of pulmonary metastases from uterine sarcomas. Gynecol Oncol. 45:202–205. 1992. View Article : Google Scholar : PubMed/NCBI
11	Hoang HL, Ensor K, Rosen G, Leon Pachter H and Raccuia JS: Prognostic factors and survival in patients treated surgically for recurrent metastatic uterine leiomyosarcoma. Int J Surg Oncol. 2014:9193232014.PubMed/NCBI
12	Reed NS: The management of uterine sarcomas. Clin Oncol (R Coll Radiol). 20:470–478. 2008. View Article : Google Scholar : PubMed/NCBI
13	Burt BM, Ocejo S, Mery CM, Dasilva M, Bueno R, Sugarbaker DJ and Jaklitsch MT: Repeated and aggressive pulmonary resections for leiomyosarcoma metastases extends survival. Ann Thorac Surg. 92:1202–1747. 2011. View Article : Google Scholar : PubMed/NCBI
14	Leitao MM, Brennan MF, Hensley M, Sonoda Y, Hummer A, Bhaskaran D, Venkatraman E, Alektiar K and Barakat RR: Surgical resection of pulmonary and extrapulmonary recurrences of uterine leiomyosarcoma. Gynecol Oncol. 87:287–294. 2002. View Article : Google Scholar : PubMed/NCBI
15	Chen H, Pruitt A, Nicol TL, Gorgulu S and Choti MA: Complete hepatic resection of metastases from leiomyosarcoma prolongs survival. J Gastrointest Surg. 2:151–155. 1998. View Article : Google Scholar : PubMed/NCBI
16	Korets SB and Curtin JP: Surgical options for recurrent uterine sarcomas. Am Soc Clin Oncol Educ Book. 1–366. 2012.
17	Yoshinaga M, Togami S, Tsuji T, Fukamachi N, Kamio M, Yanagi M and Douchi T: Clinical outcome of metastatic uterine leiomyosarcoma and carcinosarcoma in a single institute. J Obstet Gynaecol Res. 33:818–822. 2007. View Article : Google Scholar : PubMed/NCBI
18	Benson C, Ray-Coquard I, Sleijfer S, Litière S, Blay JY, Le Cesne A, Papai Z, Judson I, Schöffski P, Chawla S, et al: Outcome of uterine sarcoma patients treated with pazopanib: A retrospective analysis based on two European organisation for research and treatment of cancer (EORTC) soft tissue and bone sarcoma group (STBSG) clinical trials 62043 and 62072. Gynecol Oncol. 142:89–94. 2016. View Article : Google Scholar : PubMed/NCBI
19	Han Y, Li S, Holt HK and Wu L: Curative effect of bevacizumab combined with chemotherapy in advanced or recurrent uterine sarcoma. Mol Clin Oncol. 4:245–248. 2016. View Article : Google Scholar : PubMed/NCBI
20	Martin-Broto J, Pousa AL, de Las Peñas R, García Del Muro X, Gutierrez A, Martinez-Trufero J, Cruz J, Alvarez R, Cubedo R, Redondo A, et al: Randomized Phase II study of trabectedin and doxorubicin compared with doxorubicin alone as first-line treatment in patients with advanced soft tissue sarcomas: A spanish group for research on sarcoma study. J Clin Oncol. 34:2294–2302. 2016. View Article : Google Scholar : PubMed/NCBI
21	Schöffski P, Chawla S, Maki RG, Italiano A, Gelderblom H, Choy E, Grignani G, Camargo V, Bauer S, Rha SY, et al: Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: A randomised, open-label, multicentre, phase 3 trial. Lancet. 387:1629–1637. 2016. View Article : Google Scholar : PubMed/NCBI